Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection

By Djavan B.   Bursa B.   Seitz C.   Soeregi G.   Remzi M.   Basharkhah A.   Wolfram R.   Marberger M.  

Urology, Vol. 54, Iss. 4, 1999-10 ,pp. : 603-606

Elsevier

Access to resources Recommend Favorite

PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml

By Fang J.   Metter E.J.   Landis P.   Carter H.B.  

Urology, Vol. 59, Iss. 6, 2002-06 ,pp. : 889-893

Elsevier

Access to resources Recommend Favorite

Determination of alpha 1 -antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA

By Jung K.   Brux B.   Lein M.   Knabich A.   Sinha P.   Rudolph B.   Schnorr D.   Loening S.A.  

Urology, Vol. 53, Iss. 6, 1999-06 ,pp. : 1160-1167

Elsevier

Access to resources Recommend Favorite

Plasma levels of IGF-1, IGF-2, and IGFBP-3 in white and African-American men at increased risk of prostate cancer

By Winter D.L.   Hanlon A.L.   Raysor S.L.   Watkins-Bruner D.   Pinover W.H.   Hanks G.E.   Tricoli J.V.  

Urology, Vol. 58, Iss. 4, 2001-10 ,pp. : 614-618

Elsevier

Access to resources Recommend Favorite

Low levels of PSA predict long-term risk of prostate cancer: results from the Baltimore longitudinal study of aging

By Schroder F.H.   Wildhagen M.F.  

Urology, Vol. 59, Iss. 3, 2002-03 ,pp. : 462-462

Elsevier

Access to resources Recommend Favorite